Benecchi Christopher 4
4 · Sage Therapeutics, Inc. · Filed Feb 7, 2023
Insider Transaction Report
Form 4
Benecchi Christopher
Chief Operating Officer
Transactions
- Tax Payment
Common Stock
2023-02-03$44.16/sh−2,119$93,575→ 5,260 total - Award
Common Stock
2023-02-03+6,750→ 7,379 total
Footnotes (2)
- [F1]On October 1, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 22,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 6,750 shares.
- [F2]Reflects beneficial ownership balance which includes 414 shares purchased on June 30, 2022 and 215 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.